bm|t beteiligungsmanagement thüringen gmbh and another investor are financing the growth of HaemoSys GmbH, Jena. In the framework of an increase in capital, the two investors are providing the company with sufficient resources to reach the next milestone in the development of innovative products. The injection of funds is aimed particularly at tests for newly developed blood filters.
Non-Intrusive Therapy for Serious Chronic Diseases
HaemoSys GmbH is developing new types of medicinal products for therapeutic and diagnostic applications using versatile basic techniques.
The focus of the Jena company is the development of specific blood purification procedures providing therapy for severe disorders which are currently not curable or only unsatisfactorily so. A particular advantage of the therapy is that it has no side effects.
Initial innovative diagnostic tests by HaemoSys for the early recognition of blood clotting disorders, which often cause strokes and heart attacks are already available. After positive pre-clinical trials, HaemoSys is now preparing the clinical test phase for the blood filters.
HaemoSys was founded in 1999 and currently employs 16 staff.
Dr. Elke Bucha
Winzerlaer Str. 2
+49 (0) 3641 508–300
+49 (0) 3641 508–301